SCHEMBL7535367

SCHEMBL7535367

Cc1c(C(=O)NN=Cc2ccc(Cl)cc2)[nH]c2cccc(Cl)c12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.65
LMNA P02545 4/20 0.65
KMT2A Q03164 4/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
MEN1 O00255 3/20 0.65
THRB P10828 2/20 0.65
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 4/20 0.56
GAA P10253 2/20 0.53
MGAM O43451 1/20 0.53
SI P14410 1/20 0.53
MGAM2 Q2M2H8 1/20 0.53
FAAH O00519 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.47
TP53 P04637 1/20 0.47
NPC1 O15118 1/20 0.46
TUBB4A P04350 2/20 0.45
TUBB P07437 2/20 0.45
TUBA3C P0DPH7 2/20 0.45
TUBA1B P68363 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7676096 1.00 MAPT (0.65) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7558049 0.91 MAPT (0.54) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7558055 0.91 MAPT (0.54) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7560120 0.89 MAPT (0.62) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7560124 0.89 MAPT (0.62) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7672079 0.89 MAPT (0.69) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7528319 0.89 MAPT (0.69) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7565014 0.88 TUBB4A (0.55) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7535780 0.88 TUBB4A (0.55) MAPTLMNAKMT2ASMN1; SMN2MEN1
SCHEMBL7560001 0.82 MAPT (0.65) MAPTLMNAKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885LMNA 4535/4885KMT2A 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.